Skip to content

Association of Prophylactic Use of Stress Ulcer Drugs and Clinical Outcomes in Patients With Acute Anterior Circulation Thrombectomy

Association of Prophylactic Use of Stress Ulcer Drugs and Clinical Outcomes in Patients With Acute Anterior Circulation Thrombectomy: a Prospective, Multicenter, Observational Cohort Study

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05845372
Enrollment
2592
Registered
2023-05-06
Start date
2023-05-01
Completion date
2027-01-01
Last updated
2023-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Ischemic Stroke

Keywords

Acute Ischemic Stroke, Stress Ulcer Bleeding, Mechanical Thrombectomy

Brief summary

Ischemic stroke accounts for a relatively high proportion of strokes. In recent years, intravenous thrombolysis and endovascular therapy have significantly improved the revascularization rate in patients with large vessel occlusive cerebral infarction, but 20-50% of patients still experience ineffective revascularization. Therefore, postoperative monitoring and treatment of patients with large vessel occlusions is crucial for early recognition, management and prevention of complications. Stress ulcer bleeding is a serious complication after acute ischemic stroke, with a prevalence of 1%-5%, and a previously proven incidence of stress ulcer bleeding after ischemic stroke. Stress ulcer bleeding after ischemic stroke has been shown to be closely associated with unfavorable outcomes, such as mortality. Current national and international guidelines or consensus on the prevention of stress ulcers after acute ischemic stroke do not advocate the routine use of histamine receptor antagonists or proton pump inhibitors for the prevention of stress ulcers, but rather should be considered in the context of the patient's risk factors for stress ulcers and discontinued after the patient initiates enteral nutrition. However, there is no evidence-based medical evidence to support the risk-benefit relationship of stress ulcer drug prophylaxis in patients with mechanical thrombectomy for acute anterior circulation large vessel occlusion.

Detailed description

Stress ulcer bleeding is a serious complication after acute ischemic stroke, with a prevalence of 1%-5%, of which only 0.5%-1% require blood transfusion or result in hypotension. Stress ulcer bleeding after ischemic stroke has been shown to be associated with poor outcomes, such as mortality, and basilar artery occlusion and middle cerebral artery cerebral infarction are independent risk factors for stress ulcer bleeding after acute ischemic stroke. Guidelines or consensus on the prevention of stress ulcers after acute ischemic stroke do not advocate the routine use of histamine receptor antagonists or proton pump inhibitors for stress ulcer prevention. However, stress ulcer prophylaxis is initiated in most patients admitted to the neurological intensive care unit after mechanical embolization of acute anterior circulation large vessel occlusion. With advances such as diagnosis and early initiation of enteral nutrition, the rate of stress ulcer bleeding in patients with mechanical embolization of acute anterior circulation large vessel occlusion is significantly reduced. The relationship between the risk and benefit of SUP in patients undergoing mechanical embolization for acute anterior circulation large vessel occlusion is not yet supported by evidence-based medical evidence. Therefore, the purpose of this study was to investigate the correlation between pharmacological stress ulcer prophylaxis and clinical outcomes in patients undergoing mechanical thrombectomy for acute anterior circulation large vessel occlusion.

Interventions

None listed

Sponsors

Guangzhou Medical University
CollaboratorOTHER
The Affiliated Hospital of Inner Mongolia Medical University
CollaboratorOTHER
Second Affiliated Hospital of Wenzhou Medical University
CollaboratorOTHER
Second Affiliated Hospital of Guangxi Medical University
CollaboratorOTHER
Fujian Medical University Union Hospital
CollaboratorOTHER
Huizhou Municipal Central Hospital
CollaboratorOTHER
Haikou People's Hospital
CollaboratorOTHER
Kashgar 1st People's Hospital
CollaboratorOTHER
Ganzhou City People's Hospital
CollaboratorOTHER
Guangdong Provincial Hospital of Traditional Chinese Medicine
CollaboratorOTHER
Huadu District People's Hospital of Guangzhou
CollaboratorOTHER
Dongguan donghua hospital
CollaboratorUNKNOWN
Sinopharm North Hospital
CollaboratorUNKNOWN
Heyuan people's Hospital
CollaboratorUNKNOWN
Hainan People's Hospital
CollaboratorOTHER
Hainan Traditional Chinese Medicine Hospital
CollaboratorUNKNOWN
The First Affiliated Hospital of Hunan University of Traditional Chinese Medicine
CollaboratorOTHER
The Second Hospital University of South China
CollaboratorOTHER
Dongguan People's Hospital
CollaboratorOTHER_GOV
Yueyang People's Hospital
CollaboratorUNKNOWN
Nanfang Hospital, Southern Medical University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Age ≥18 years. 2. Within 24 hours of onset. Meet the criteria for diagnosis of acute ischemic stroke in the China Acute Ischemic Stroke Diagnosis and Treatment Guidelines 2018. 3. Meet the indications for mechanical thrombectomy in the Chinese Guidelines for Early Endovascular Interventions in Acute Ischemic Stroke 2022. 4. Treated with mechanical thrombectomy. 5. NIHSS score ≥ 6 at onset of illness. 6. Sign an informed notice.

Exclusion criteria

Allergy to drug ingredients. Women who are pregnant or breastfeeding. Life expectancy of less than 3 months due to other non-ischemic stroke diseases such as malignancy, severe liver or renal failure. Have participated in other interventional clinical studies (affecting the outcome of this cohort study). Participants who were judged by the investigator to be unsuitable for participation in this study.

Design outcomes

Primary

MeasureTime frameDescription
90-day mortality after onset90-day after onsetProportion of enrolled patients who died 90 days after onset of disease.
Incidence of stroke-associated pneumoniawithin 7-day of onsetIncidence of non-mechanically ventilated stroke patients with new pneumonia within 7-day of onset

Secondary

MeasureTime frameDescription
Incidence of clinically significant bleedingwithin 7-day of onsetOne of the following 4 symptoms occurs within 24 hours of bleeding from a stress ulcer (in the absence of other causes):1. A decrease of ≥ 20 mmHg in any one of systolic, diastolic and mean arterial pressure. 2.Initiation of blood pressure boosters or 20% increase in medication dose.3. Decreased hemoglobin ≥ 2 g/d((1.24 mmol/l). 4.Infusion of erythrocytes ≥ 2 U.
90-day mRS score change90-day after onsetModified Rankin Scale score change within 90 days after onset in patients who were eligible for inclusion criteria
Incidence of stress ulcer bleeding7-day after onsetCoffee-like residue/black stool/blood in stool within 7-day after onset and more than 2 consecutive positive fecal/gastric fluid occult blood
1-year post-onset mortality1 year after onsetMortality at 1 year after onset in patients who were eligible for inclusion criteria
Incidence of adverse related events such as pneumonia or myocardial ischemia 1 year after onset1 year after onsetIncidence of adverse related events such as pneumonia or myocardial ischemia 1 year after onset in patients who were eligible for inclusion criteria
Incidence of early neurological deteriorationwithin 72 hours after onsetIncreased score of National Institutes of Health Stroke Scale within 72h after onset ≥ 4
Incidence of unfavorable functional prognosis at 90 days after onset90-day after onsetIncidence of unfavorable functional prognosis at 90 days after onset

Countries

China

Contacts

Primary ContactSuyue Pan, M.D., Ph.D.
pansuyue@smu.edu.cn13556184981

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026